Leandro, M;
Isenberg, DA;
(2021)
Rituximab - The first twenty years.
Lupus
10.1177/0961203320982668.
(In press).
Preview |
Text
Isenberg_Rituximab - The First 20 Years Clean Copy 06.11.2020.pdf - Accepted Version Download (220kB) | Preview |
Abstract
It is now two decades since Rituximab was first used in the treatment of patients with systemic lupus erythematosus. There have been many challenges but in spite of failing to meet its primary endpoints in two clinical trials it is widely used for many aspects of lupus, its side-effects and the possibility that combining it with Benlysta may be of value. We also consider the proposal that it may provide a useful initial therapy. In this review, we consider the place of Rituximab in the treatment of lupus and anticipate how developments in fully-humanized anti-CD20 monoclonals may well extend the "therapeutic life" of B-cell depletion as a viable treatment option.
| Type: | Article |
|---|---|
| Title: | Rituximab - The first twenty years |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1177/0961203320982668 |
| Publisher version: | http://dx.doi.org/10.1177/0961203320982668 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Anti-DNA antibodies, cutaneous lupus, renal lupus |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10122024 |
Archive Staff Only
 |
View Item |
